Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Reports 2018 Financial Results and Provides Corporate Update
March 6, 2019
Xenon to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update
February 27, 2019
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
February 26, 2019
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101
January 28, 2019
Xenon Outlines 2019 Key Milestones
January 6, 2019
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
